IFN-α2 Antibody (N27): sc-57219
- IFN-α2 Antibody (N27) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against full length IFN-α2 of human origin
- recommended for detection of IFN-α2 of human origin by FCM; non cross-reactive with IFN-α1
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP, m-IgG1 BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for IFN-α2 Antibody (N27). These reagents are now offered in bundles with IFN-α2 Antibody (N27) (see ordering information below).
IFN-α2 Antibody (N27) is a mouse monoclonal IgG1 antibody that detects IFN-α2 in human samples through flow cytometry (FCM). IFN-α2 is a crucial member of the type I interferon family, playing a significant role in immune response, particularly in antiviral defense. Various cells, including leukocytes, produce this cytokine in response to viral infections, activating immune cells, enhancing major histocompatibility complex (MHC) molecule expression, and promoting T cell development. IFN-α2 has important therapeutic applications in treating conditions like chronic hepatitis C and certain types of cancer, demonstrating significant immune response modulation and antitumor effects. Post-translational modifications, such as glycosylation, can influence IFN-α2′s stability, activity, and receptor interactions, highlighting this protein′s complexity in therapeutic contexts. Anti-IFN-α2 antibody (N27) serves as an essential tool for researchers studying immune response dynamics and interferon therapeutic potential.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IFN-α2 Antibody (N27) References:
- Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. | Wussow, PV., et al. 1991. Br J Haematol. 78: 210-6. PMID: 2064959
- VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma. | Preis, P., et al. 1989. Onkologie. 12: 27-9. PMID: 2654788
- Pretreatment of UC-MSCs with IFN-α2 improves treatment of liver fibrosis by recruiting neutrophils. | Xie, Y., et al. 2023. J Transl Med. 21: 832. PMID: 37980535
- Recombinant protein synthesis and isolation of human interferon alpha-2 in cyanobacteria. | Majhi, BK. and Melis, A. 2024. Bioresour Technol. 400: 130664. PMID: 38583672
- IFN-α2 Autoantibody Screening and Functional Evaluation in Viral and Bacterial Infections. | Cockx, M., et al. 2024. J Appl Lab Med. 9: 977-989. PMID: 39114898
- Interferon receptor interaction. Internalization of interferon alpha 2 and modulation of its receptor on human cells. | Sarkar, FH. and Gupta, SL. 1984. Eur J Biochem. 140: 461-7. PMID: 6327298
- Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. | Hayden, FG., et al. 1984. Antimicrob Agents Chemother. 25: 53-7. PMID: 6703684
- Potential uses of interferon alpha 2 as adjuvant therapy in cancer. | Agarwala, SS. and Kirkwood, JM. 1995. Ann Surg Oncol. 2: 365-71. PMID: 7552628
- Interferon-alpha 2 produced by normal human leukocytes is predominantly interferon-alpha 2b. | Dipaola, M., et al. 1994. J Interferon Res. 14: 325-32. PMID: 7897251
- Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. | Antonelli, G., et al. 1996. Clin Exp Immunol. 104: 384-7. PMID: 9099919
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IFN-α2 Antibody (N27) | sc-57219 | 200 µg/ml | $322.00 | |||
IFN-α2 Antibody (N27): m-IgG Fc BP-HRP Bundle | sc-537136 | 200 µg Ab; 10 µg BP | $361.00 | |||
IFN-α2 Antibody (N27): m-IgGκ BP-HRP Bundle | sc-534328 | 200 µg Ab; 40 µg BP | $361.00 | |||
IFN-α2 Antibody (N27): m-IgG1 BP-HRP Bundle | sc-545027 | 200 µg Ab; 20 µg BP | $361.00 | |||
IFN-α2 Antibody (N27) FITC | sc-57219 FITC | 200 µg/ml | $336.00 | |||
IFN-α2 Antibody (N27) PE | sc-57219 PE | 200 µg/ml | $349.00 |